Document:

Exhibit 10.12

 

 

June 12, 2016

 

Robert J. Gould, Ph.D.

[**]

 

Re:  Offer of Employment

 

Dear Robert:

 

Fulcrum Therapeutics, Inc. (the “Company”) is pleased to confirm its offer to employ you as President and Chief Executive Officer. As President and Chief Executive Officer you will be a member of the Board and report to the Company’s Board of Directors (the “Board”). Your start date will be no later than June 20, 2016 pending completion of all meetings with team members and signing of the new agreed upon Agreement with Epizyme.

 

Responsibilities are expected to include, but may not limited to, the following:

 

·                  Oversee and integrate all company activities to ensure Fulcrum meets its research, development, and business milestones by focusing on value creation for our founders, employees, partners, investors and most importantly,  making a difference in patients’ lives

 

·                  Work with the Board and senior management to develop and communicate a compelling vision, strategic direction and company business plan; continually evaluate alternative strategies; identify competitive issues; capitalize on the product engine and develop and implement operating plans to achieve objectives

 

·                  Build a robust organization by ensuring that qualified research & development and business talent are recruited hired and retained.  Work with the Board and the senior management team to manage uncertainty while maintaining an entrepreneurial environment; manage performance of team by providing feedback, teaching and development opportunities

 

·                  Foster an internal atmosphere that supports individual accountability, transparency, open communication and respect to enable employees to focus on the Company’s culture and mission

 

·                  Build and maintain a “Group Genius” environment for our founders, employees, advisors, key opinion leaders, partners and investors where everyone expresses their ideas and opinions and where we ultimately integrate these ideas to achieve the best plans and solutions for our patients

 

·                  Develop, build and lead strategic partnerships with external companies to complement Fulcrum’s capability, to raise dollars for building the company and to bring important products to the patients we serve

 

 

·                  Serve as the primary spokesperson for company, establishing and communicating the company’s vision and image, and enhancing its visibility among potential partners

 

Your compensation for this position will be at the rate of $420,000 a year, payable in accordance with the Company’s normal pay schedule, which the Company currently expects will be bi-weekly.  All payments are subject to legally required tax withholdings.  It is expected that, when an annual bonus program is approved by the Board of Directors, you will be eligible for a target bonus at 35% of your annual compensation, based upon the achievement of corporate and individual goals, as agreed by the Board of Directors. You will be eligible to participate each year in any annual bonus plan adopted by the Company and the Company, subject to financial, business, and other circumstances and factors.

 

After Series A funding, you will be issued restricted stock grant for 3,000,000 shares of Fulcrum Therapeutics, Inc. common stock (the “Shares”), subject to approval of the Company’s Board of Directors, at an exercise or purchase price equal to the fair market value of the Company’s common stock on the date of grant or issuance, subject to the standard terms and conditions of Fulcrum Therapeutics, Inc. Stock Incentive Plan and form of stock option or restricted stock agreement, including vesting, subject to continued employment. The Shares shall vest over four years at the rate of 25% on the first anniversary of the commencement date of your employment and an additional 6.25% per quarter for the next twelve successive quarters of employment when, after four full years of employment, the Shares will be fully vested.  The Share grant will be brought to the Board of Directors for approval soon after you begin employment with the Company.

 

The Company will offer a comprehensive benefits program and you will be eligible to participate in the program to the extent that the company establishes them soon after the completion of the Series A financing.  You will accrue 15 paid vacation days each year for the first 5 years of service and receive all paid holidays annually in accordance with the company holiday schedule.

 

It is understood that you are an “at-will” employee.  You are not being offered employment for a definite period of time, and either you or the Company may terminate the employment relationship at any time and for any reason, with or without Cause or prior notice and without additional compensation to you, other than as provided below.

 

(a)  the Company may terminate your employment for “Cause” (as defined below) upon written notice to you effectively immediately, in which case you will not be entitled to receive any form of payment other than your earned compensation through your date of separation;

 

2

 

(b)  you may terminate your employment voluntarily other than for “Good Reason” (as defined below) upon at least thirty (30) days’ prior written notice to the Company, in which case you will not be entitled to receive any form of payment other than your earned compensation through your date of separation; and

 

(c) Notwithstanding the foregoing, in the event that the Company terminates your employment without Cause, then, subject to you entering into and complying with a separation agreement and general release in a form provided by the Company, you will be entitled to a severance pay in an amount equal to: (i) twelve months of your then base salary as of the date of termination, such amount to be paid in equal installments over a twelve (12) month period after the date of your termination in accordance with the Company’s usual payroll practices and periods, subject to applicable taxes and withholding, (ii) payment for twelve (12) months of monthly COBRA premiums at the same rate as the Company pays for active employees for you and your eligible dependents, subject to applicable COBRA terms and in compliance with applicable non-discrimination or other requirements under the Internal Revenue Code (the “Code”), the Patient Protection and Affordable Care Act, or the Health Care and Education Reconciliation Act.

 

(d) For purposes of this letter agreement:

 

“Cause” means:

 

Your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) your conviction of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform your assigned duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the Company, for thirty (30) days after written notice given to you by the Company describing such failure in reasonable detail; (iv) your gross negligence, willful misconduct or insubordination with respect to the Company that results in or is reasonably anticipated to result in material harm to the Company; or (v) your material violation of any provision of any agreement(s) between you and the Company relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions.

 

(e) For purposes of this letter, “Good Reason” means, in the context of your resignation from your employment position with the Company, a resignation that occurs within thirty (30) days following: (i) a change in the principal location at which you provide services to the Company beyond fifty (50) miles from Cambridge, MA; (ii) a material reduction in your compensation or a material reduction in your benefits, except such a reduction in connection with a general reduction in compensation or other benefits of all senior executives of the Company; (iii) a material breach of this letter by the Company that has not been cured within ten (10) days after written notice thereof by you to the Company; or (iv) a failure by the Company to obtain the assumption of this letter by any successor to the Company.

 

(f) The time for payment, or schedule for payment, of any severance payments due hereunder may not be accelerated, except as provided for in the Treasury Regulations promulgated under Section 409A of the Internal Revenue Code of 1986 (the “Code11), or any law replacing or superseding such Section or

 

3

 

regulations. Notwithstanding the preceding provisions of this Section 6(d), in the case that the Company becomes a publicly traded company and you are deemed a “specified employee” (as defined in Section 409A(2)(B)(i) of the Code), no severance payment may be made earlier than the date which is six (6) months after the termination of employment hereunder (or, if earlier, the date of the death of the Executive) if and to the extent required by applicable law or other rules of any stock exchange upon which any of shares of the Company’s capital stock are then traded.

 

Enclosed is a “Non-Solicitation, Non-Competition, Confidentiality and Assignment Agreement” (the “Employee Agreement”).  This offer of employment is conditioned on your willingness to enter into and abide by the terms of the Employee Agreement, the terms of which are incorporated into this offer letter.

 

In making this offer, the Company understands, and in accepting it you represent that you are not under any obligation to any former employer or any person or entity which would prevent, limit, or impair in any way the performance by you of your duties as an employee of the Company.

 

The Immigration Reform and Control Act requires employers to verify the employment eligibility and identity of new employees.  You will be required to complete a Form I-9 which will be provided to you before the Start Date.  Please bring the appropriate documents listed on that form with you when you report for work.  We will not be able to employ you if you fail to comply with this requirement.

 

This offer letter and the Employee Agreement and Equity Documents referenced above constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.  Neither this offer letter nor the Employee Agreement may be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company, although, consistent with your at-will employment, your job duties, title, reporting relationship, compensation and benefits may change from time to time, at the Company’s option.

 

Please indicate your acceptance of this offer by signing and returning the enclosed copy of this letter and the Employee Agreement no later than “-” based on when he is scheduled to come back to meet the rest of the team.   You may indicate your acceptance of this offer by signing on the appropriate space below and returning a signed, scanned copy of this letter and the Employee Agreement to Chris Robinson, [**] and Susan O’Connor at [**].

 

4

 

We look forward to your joining the Company and are pleased that you will be working with us.

 

Very truly yours,

 

 

Mark Levin

Interim Chief Executive Officer

Fulcrum Therapeutics, Inc.

 

Accepted and Agreed:

 

 

	
/s/   Robert J. Gould
    	
 
    
	
Robert   J. Gould, Ph.D.
    	
 
    

 

 

	
13 June 2016
    	
 
    
	
Date
    	
 
    

 

5Exhibit 10.13

 

 

December 6, 2018

 

Bryan Stuart

[**]

 

Re:  Offer of Employment

 

 

Dear Bryan,

 

Fulcrum Therapeutics, Inc. (the “Company”) is pleased to confirm its offer to employ you as a Chief Operating Officer reporting to Robert Gould, President & CEO. As the COO you will be a key business partner with the CEO in building the company, setting and driving corporate strategy and long-range planning, and helping to lead and maintain strong relationships with the financial and business community.  You will partner with the CEO and the leadership team to develop Fulcrum’s long-term business strategy and assure continuous integration across Corporate Development, Scientific and Financial strategies. In this role, the COO is a key strategic partner focusing on future value creation for Fulcrum. This includes oversight for portfolio strategy including project planning and management, business development, operations, and patient advocacy.

 

Your effective date of hire as an employee will be a date agreed to by you and the Company. For purposes of this offer letter, the actual first day of your employment shall be referred to as the “Start Date”. Your start date will be no later than December 17, 2018. Your normal place of work will be at the Company’s offices in Cambridge, MA.

 

Your annual compensation for this position will be at the rate of $400,000 per year, payable in accordance with the Company’s normal pay schedule, which currently is semi-monthly (“Base Salary”).  All payments are subject to legally required tax withholdings. In addition to your Base Salary, you will be eligible to earn an annual target bonus of up to 35% of your Base Salary. The actual amount of such bonus, if any, will be determined by the Company’s Board of Directors (the “Board”) and your manager in their good faith discretion, based upon achievement of corporate and individual goals. The bonus, if any, shall be paid at a time and in a manner as determined by the Company in its sole discretion. You must be employed by Fulcrum at the time of any such bonus payment to be eligible for any such payment. Because your start date is after October 1, 2018, you will not be eligible to participate in our 2018-year end compensation program (base salary/bonus/equity); you will be eligible to begin participating in 2019.

 

 

 

You will be issued a stock option grant for 2,125,000 shares of Fulcrum Therapeutics, Inc. stock (the “Options”), subject to approval of the Company’s Board of Directors, at an exercise price equal to the fair market value of the Company’s common stock on the date of grant or issuance, subject to the standard terms and conditions of Fulcrum Therapeutics, Inc. Stock Incentive Plan and form of stock option agreement, including vesting, subject to continued employment. Subject to the terms of the stock option agreement and your continued employment, the Options shall vest over four years at the rate of 25% on the first anniversary of the commencement date of your employment and an additional 6.25% per quarter for the next twelve successive quarters of employment when, after four full years of employment, the Options will be fully vested. The Options grant will be brought to the Board of Directors for approval soon after you begin employment with the Company.

 

You will be eligible to participate in the Company’s health insurance programs as well as the life, AD&D, short and long-term disability plans, along with the Company’s 401k plan, subject to the terms of those plans. As of January 1, 2019, Fulcrum now offers employees a discretionary vacation time off program. In addition, you will receive paid holidays in accordance with the annual company holiday schedule. Current Benefits Summary is attached. Benefits are subject to change at any time in the Company’s sole discretion.

 

It is understood and agreed that that you are an “at-will” employee. You are not being offered employment for a definite period of time, and either you or the Company may terminate the employment relationship at any time and for any reason, with or without cause or prior notice and without additional compensation to you, other than as provided below:

 

Notwithstanding the foregoing, in the event that the Company terminates your employment without Cause (as defined below), and for the avoidance of doubt, not due to death or disability, then, subject to you entering into and complying with a separation agreement and general release in a form provided by the Company no later than sixty (60) days following termination of employment, you will be entitled to severance pay in an amount equal to:

 

·                  Six (6) months of your then current Base Salary, less lawful deductions, paid in equal installments in accordance with the Company’s standard payroll practice over the six-month period immediately following your termination of employment (the “Severance Payments”); provided, that the first installment payment of the Severance Payments shall be made on the sixtieth (60th) day after the date of you termination, and will include payment of any installment payments that were otherwise due prior thereto; plus

 

·                  subject to (i) your timely election of continuation coverage under COBRA, and (ii) your continued copayment of premiums at the same level and cost to you as if you were an employee of the Company (excluding, for purposes of calculating cost, an employee’s ability to pay premiums with pre-tax dollars), continued payment by the

 

 

Company of your (and your dependents, if applicable) health, insurance coverage during the six (6) month period following the date of termination to the same extent that the Company paid for such coverage immediately prior to the date of termination, in a manner intended to avoid any excise tax under Section 4980D of the Internal Revenue Code of 1986, as amended, subject to the eligibility requirements and other terms and conditions of such insurance coverage.

 

For purposes of this letter agreement:

 

“Cause” means:

 

(i) Your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) your conviction of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your gross negligence, willful misconduct or insubordination with respect to the Company that results in or is reasonably anticipated to result in material harm to the Company; or (iv) your material violation of any provision of any agreement(s) between you and the Company relating to nonsolicitation, nondisclosure and/or assignment of inventions.

 

Section 409A.

 

Although the Company does not guarantee the tax treatment of any payments under this letter agreement, the intent of the Company is that the payments and benefits under this letter agreement be exempt from, or comply with, Section 409A of the Internal Revenue Code of 1986, as amended, and all Treasury Regulations and guidance promulgated thereunder (“Code Section 409A”) and to the maximum extent permitted the Agreement shall be limited, construed and interpreted in accordance with such intent. In no event whatsoever shall the Company or its affiliates or their respective officers, directors, employees or agents be liable for any additional tax, interest or penalties that may be imposed on you by Code Section 409A or damages for failing to comply with Code Section 409A.

 

Notwithstanding any other provision of this letter agreement to the contrary, to the extent that any reimbursement of expenses constitutes “deferred compensation” under Code Section 409A, such reimbursement shall be provided no later than December 31 of the year following the year in which the expense was incurred. The amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year. The amount of any in-kind benefits provided in one year shall not affect the amount of in-kind benefits provided in any other year.

 

 

For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section l.409A-2(b)(2)(iii)), the right to receive payments in the form of installment payments shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment shall at all times be considered a separate and distinct payment.

 

Notwithstanding any other provision of this letter agreement to the contrary, if at the time of your separation from service (as defined in Code Section 409A), you are a “Specified Employee”, then the Company will defer the payment or commencement of any nonqualified deferred compensation subject to Code Section 409A payable upon separation from service (without any reduction in such payments or benefits ultimately paid or provided to you) until the date that is six (6) months following separation from service or, if earlier, the earliest other date as is permitted under Code Section 409A (and any amounts that otherwise would have been paid during this deferral period will be paid in a lump sum on the day after the expiration of the six (6) month period or such shorter period, if applicable).

 

This offer of employment is contingent upon you’re signing the Employee Confidentiality and Assignment Agreement (the “Employee Agreement”) and receipt of a satisfactory outcome of pre-employment screening activities including favorable reference checks of former employment, verification of your ability to work in the United States, education and criminal history check. In making this offer, the Company understands, and in accepting it you represent that you are not under any obligation to any former employer or any person or entity which would prevent, limit, or impair in any way the performance by you of your duties as an employee of the Company.

 

The Immigration Reform and Control Act requires employers to verify the employment eligibility and identity of new employees. You will be required to complete a Form I-9 which will be provided to you before the Start Date. Please bring the appropriate documents listed on that form with you when you report for work. We will not be able to employ you if you fail to comply with this requirement.

 

This offer letter and the Employee Agreement and Equity Documents referenced above constitute the complete agreement between you and the Company, contain all the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. Neither this offer letter nor the Employee Agreement may be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company, although, consistent with your at-will employment, your job duties, title, reporting relationship, compensation and benefits may change from time to time, at the Company’s option.

 

 

Please indicate your acceptance of this offer by signing and returning the enclosed copy of this letter and the Employee Agreement. You may indicate your acceptance of this offer by signing on the appropriate space below and returning a signed, scanned copy of this letter to Kim Hazen at [**].

 

We look forward to your joining Fulcrum and are pleased that you will be working with us.

 

Very truly yours,

 

	
/s/   Robert Gould
    	
 
    
	
 
    	
 
    
	
Robert   Gould, Ph.D.
    	
 
    
	
President &   CEO
    	
 
    

 

 

Accepted and Agreed:

 

	
/s/   Bryan Stuart
    	
 
    	
12/6/18
    
	
Bryan   Stuart
    	
 
    	
Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]